Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1834845 and BAY 1830839 in Healthy Males with IRAK4 Challenge
NCT05003089Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of zabedosertib and BAY1830839 in dermatitis and Eczema (4 arms), sponsored by Bayer. Primary endpoints: Average change of perfusion/basal flow at 72 hour, Average change of erythema score at 72 hour and 2 more. Started Jun 2021; status: completed.
02
Drugs
zabedosertibBAY1830839
03
Conditions
dermatitisEczema
Beyond the preview
Go deeper on NCT05003089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003089.